Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related macular degeneration, which it co-markets with Bayer. The Eylea franchise -- including a ...

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

but that was offset by higher rates of inflammatory reactions in the eyes – some of which could be sight threatening – compared to rival anti-VEGF therapy Eylea (aflibercept) from Bayer and ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

Nationwide Building Society is handing out £50 to members (Mike Egerton/PA) (PA Archive) High street lender Nationwide is ...

German online fashion giant Zalando has successfully acquired more than 90% of the share capital of its competitor, About You ...